At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 413 enrolled
Drug / intervention
CHIKV VLP/adjuvant +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age
In Brief
A Phase 3 clinical trial evaluating CHIKV VLP/adjuvant and Placebo for Chikungunya Virus. Completed, enrolled 413 participants across 10 sites.
Detailed Summary
The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChikungunya Virus
CountriesUnited States
CollaboratorsEmergent BioSolutions
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionJun 2023
Study CompletionAug 2023
TodayJul 2026
First PostedApr 27, 2022
Enrollment StartMay 12, 2022
Primary CompletionJun 19, 2023
Study CompletionAug 8, 2023
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.2 years ago
Interventions
CHIKV VLP/adjuvantbiological
PXVX0317 vaccine is comprised of chikungunya virus virus-like particles (CHIKV VLP), adsorbed on aluminum hydroxide adjuvant
Placebobiological
Placebo is comprised of formulation buffer